Evidence map›Paper›PMID 35889017›Full record

ReviewMicroorganisms2022

Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.

Liudmila A Alexandrova, Anastasia L Khandazhinskaya, Elena S Matyugina, Dmitriy A Makarov, Sergey N Kochetkov

Open access · goldAbstract readReview
In one paragraph

Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Challenging the Biginelli scaffold to surpass the first line antitubercular drugs:Journal of enzyme inhibition and medicinal chemistry · 2024
    Article
  6. New Biocides Based onInternational journal of molecular sciences · 2024
    Article
  7. Microorganisms · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Liudmila A AlexandrovaEngelhardt Institute of Molecular Biology RAS, 32 Vavilov Str., 119991 Moscow, Russia.
Anastasia L KhandazhinskayaEngelhardt Institute of Molecular Biology RAS, 32 Vavilov Str., 119991 Moscow, Russia.ORCID 0000-0003-1452-0253
Elena S MatyuginaEngelhardt Institute of Molecular Biology RAS, 32 Vavilov Str., 119991 Moscow, Russia.ORCID 0000-0002-4981-7316
Dmitriy A MakarovEngelhardt Institute of Molecular Biology RAS, 32 Vavilov Str., 119991 Moscow, Russia.ORCID 0000-0003-2438-1146
Sergey N KochetkovEngelhardt Institute of Molecular Biology RAS, 32 Vavilov Str., 119991 Moscow, Russia.ORCID 0000-0002-7443-6961
Engelhardt Institute of Molecular Biology · RU

Funding

Russian Foundation for Basic Research 20-04-00094Russian Science Foundation 19-74-10048
6 · The paper itself

Abstract

Tuberculosis (TB) is the oldest human infection disease. Mortality from TB significantly decreased in the 20th century, because of vaccination and the widespread use of antibiotics. However, about a third of the world's population is currently infected with

Indexed as

drug resistanceinhibitorsmycobacteriaMycobacterium tuberculosisnucleoside analoguesthymidine monophosphate kinasethymidylate synthase

Identifiers

PMID35889017
PMCPMC9322969
OpenAlexW4283660295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.